Stock Market Update

[BRIEFING.COM] The major averages continue to trade mostly lower, with the S&P 500 (-0.4%) and Nasdaq Composite (-1.1%) charting session lows.

In corporate news, AbbVie (ABBV 230.11, +13.62, +6.29%) is trading higher after agreeing to acquire Apogee Therapeutics (APGE 132.71, +42.33, +46.84%) for $135.11 per share in cash, a deal that values Apogee at about $10.9 billion and signals a willingness to spend aggressively to deepen its immunology pipeline. AbbVie framed the acquisition as complementary to its existing immunology portfolio and as a way to accelerate its respiratory presence, with lead asset zumilokibart in development for atopic dermatitis and a combination program in asthma. AbbVie continues to aggressively deploy capital to reinforce its position as one of the premier immunology companies in biopharma.

The acquisition of Apogee is less about near-term earnings and more about securing future growth opportunities in large inflammatory disease markets where AbbVie already possesses significant commercial expertise. Investors are likely to focus on the hefty $10.9 billion price tag and the lengthy timeline before expected EPS accretion in 2032, but management appears willing to sacrifice near-term returns to strengthen its post-Humira growth profile.